Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRISM-TB
NCT06441006Phase 3Recruiting
- Sponsor
- University of California, San Francisco
- Start
- Oct 2025
- Primary completion
- Aug 2031
- Modality
- Prodrugs/Conditional Activator Small Molecules, Orthosteric Ligands
- Countries
- 5
01
Overview
A Phase 3 trial of bedaquiline, linezolid, moxifloxacin in Tuberculosis (TB), sponsored by University of California, San Francisco. Started Oct 2025; status: recruiting.
02
Drugs
bedaquilinelinezolidmoxifloxacin
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT06441006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06441006.